Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.41 |
| ▸ | CETP | P11597 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PTGIR | P43119 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946101 | 1.00 | PTGDR2 (0.43) | PTGDR2P2RX3P2RX2TBXA2RPTGDR | |
| SCHEMBL1942304 | 0.94 | P2RX3 (0.41) | PTGDR2P2RX3P2RX2TBXA2RPTGDR | |
| SCHEMBL1008659 | 0.94 | PTGDR2 (0.50) | PTGDR2P2RX3P2RX2TBXA2RPTGDR | |
| SCHEMBL1943229 | 0.94 | PTGDR2 (0.50) | PTGDR2P2RX3P2RX2TBXA2RPTGDR | |
| SCHEMBL1944800 | 0.94 | P2RX3 (0.41) | PTGDR2P2RX3P2RX2TBXA2RPTGDR | |
| SCHEMBL1009037 | 0.94 | P2RX3 (0.41) | PTGDR2P2RX3P2RX2TBXA2RPTGDR | |
| SCHEMBL1942276 | 0.94 | PTGDR2 (0.50) | PTGDR2P2RX3P2RX2TBXA2RPTGDR | |
| SCHEMBL1943384 | 0.87 | PTGDR2 (0.46) | PTGDR2TBXA2RPTGDRCETPSCN9A | |
| SCHEMBL1010011 | 0.86 | PTGDR2 (0.48) | PTGDR2P2RX3P2RX2TBXA2RPTGDR | |
| SCHEMBL1944156 | 0.86 | PTGDR2 (0.48) | PTGDR2P2RX3P2RX2TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885P2RX3 128/4885P2RX2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.